302962-49-8 Usage
Uses
Dasatinib is used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is particularly effective for patients who are resistant or intolerant to other leukemia medications, such as imatinib mesylate. Dasatinib is also used as a first-line treatment for certain types of CML and in children with this condition. Additionally, it is used to treat a specific type of acute lymphoblastic leukemia (ALL) in patients who can no longer benefit from other leukemia medications or who cannot take these medications due to side effects.
Dasatinib is a multi-targeted inhibitor that targets Abl, Src, and c-Kit, with IC50 values of less than 1 nM, 0.8 nM, and 79 nM, respectively. It directly targets both wild-type and mutant c-Abl kinase domains, blocking the action of an abnormal protein that signals cancer cells to multiply, thus helping to stop the spread of cancer cells.
Dasatinib is available in 20-, 50-, and 70-mg tablets for oral administration. Although it is more potent than imatinib, its bioavailability is lower, ranging between 14% to 34%. The drug is extensively metabolized, with up to 29 metabolites resulting from oxidation by primarily CYP3A4 and phase II conjugation. Dasatinib is 95% protein-bound, with a terminal half-life of 3 to 5 hours, and the majority of the drug and metabolites are eliminated in the feces.
Common side effects of Dasatinib include skin rash, nausea, diarrhea, and fatigue. Serious side effects may include myelosuppression appearing as neutropenia and thrombocytopenia, bleeding of the brain and GI tract, and fluid retention.
Used in Pharmaceutical Industry:
Dasatinib is used as an antineoplastic agent for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) due to its potent inhibition of multiple tyrosine kinases, including BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFR-B.
Leukemia drug
Dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors. October 28, 2010 ,the FDA approved dasatinib (Sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed Philadelphia chromosome-positive called chronic myeloid leukemia (Ph + CP-CML) . The disease is a blood and bone marrow disease associated with genetic abnormality . An open-label randomized clinical trial conducted in patients with CP-CML evaluated the ?safety and efficacy of dasatinib . Common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, headache, musculoskeletal pain, and rash. October 11, 2011, the US Food and Drug Administration (FDA) said the leukemia drug dasatinib (Sprycel, Bristol-Myers Squibb Company) might increase pulmonary arterial hypertension (PAH) risk. Pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . PAH symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms ?from other similar symptoms. Since 2006 Dasatinib was approved in the US market ,there had been ?12 associated pulmonary hypertension events ?,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib. The above information is edited by the lookchem of Tian Ye.
Mechanism of Action
Dasatinib (former BMS 354825), or N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2- hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carbox- amide monohydrate (C22H26ClN7O2S), is an orally available small-molecule multitargeted kinase inhibitor. Dasatinib was discovered by and named after Jagabandhu Das (Lombardo et al. 2004; Das et al. 2006) as part of an effort to develop potent inhibitors of SRC family kinases (SFKs).The compound targets the SRC family of kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK). In addition, and clinically more significant, da- satinib inhibits BCR-ABL with greater potency compared to other BCR-ABL inhibitors.It also inhibits receptor tyrosine kinases (c-KIT, PDGFR, DDR1 and 2, c-FMS, ephrin receptors) and TEC family kinases (TEC and BTK) (Table 1).Preclinical studies suggest that dasatinib induces apoptosis in only a small subset of cell lines. Inhibition of migration, invasion, and cell adhesion by da- satinib is reported more frequently (Johnson et al. 2005; Nam et al. 2005; Serrels et al. 2006). It has been demonstrated that dasatinib induces defects in spindle generation, cell cycle arrest, and centrosome alterations in leukemic cells, tumor cell lines, and also in normal cells. These effects are not attributable to the inhi- bition of a single kinase; rather it is expression of nonspecific effects on multiple kinases (Fabarius et al. 2008).In a nude mouse model of prostate cancer, tumor growth and the development of lymph node metastasis were inhibited by dasatinib (Park et al. 2008). In addition, Dasatinib acts also on the tumoral microenvironment, especially in bone, where dasatinib inhibits osteoclastic activity and favors osteogenesis, exerting a bone-protecting effect (Metcalf et al. 2002).
Pharmacokinetics
Dasatinib is administered orally. The drug is rapidly absorbed, peak plasma concentrations occur 0.5-3 h after administration. The intake of food is not relevant for pharmacokinetics of dasatinib. In a dose range of 25-120 mg twice daily, the area under the plasma concentration—time curve (AUC) increased proportionally. The drug is extensively metabolized in the liver, predominantly by cytochrome P 450 (CYP) 3A4, only 30 % remain unchanged. The metabolites of the compound are unlikely to play a pharmacologic role. There were linear elimination characteristics over the above-mentioned dose range with a terminal elimination half-life of 5-6 h. Elimination occurs mostly in the feces (85 %) only little in urine (4 %). Dasatinib is excreted as metabolites, only 19% of a dose was recovered as unchanged drug in the feces (SprycelòBMS 2012).
Toxicology
Dasatinib has a unique safety profile and since early clinical trials some AEs have been consistently reported in patients receiving dasatinib including myelosup- pression, fluid retention, pleural effusion, gastrointestinal disorders, fatigue, headache, musculoskeletal disorders, rash, and infection (Table 8). Some bleeding events have also been reported. More recently, cases of pulmonary arterial hypertension (PAH), a subcategory of pulmonary hypertension (PH), have been reported in a small number of patients receiving dasatinib (Galie et al. 2009; McLaughlin et al. 2009; Fang et al. 2012). In clinical trials of first-line and second- line dasatinib, most AEs occurred within 12—24 months of treatment and were managed with dose modifications (Kantarjian et al. 2012; Shah et al. 2012; SprycelòBMS 2012).Small Molecules in Oncology
Drug Interactions
Dasatinib is a substrate and an inhibitor of CYP3A4. Therefore, there is a potential for interaction with other concomitantly administered drugs that are metabolized primarily by or modulate the activity of CYP3A4.Systemic exposure to dasatinib is increased if it is coadministered with drugs that are inhibitors of CYP 3A4 (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole).If coadministered with drugs that induce CYP 3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or Hypericum perforatum, also known as St. John’s Wort), dasatinib AUC is reduced. It was reduced by 82% when coadministered with rifampicin.Dasatinib AUC was reduced when coadministered with H2-blockers/protonpump inhibitors, or antacids. Concomitant administration of famotidin reduced dasatinib AUC by 61%, coadministration of aluminum hydroxide by 55%.Dasatinib is an inhibitor of CYP3A4. Substrates of CYP3A4 with a narrow therapeutic index should be administered with caution in patients receiving dasatinib. Drugs that rank among that list are alfentanil, astemizole, terfenadine, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloid (ergotamine, dihydroergotamine) (SprycelòBMS 2012).
Clinical Use
#N/A
Synthesis
A concise and efficient route was
developed for the synthesis of dasatinib. Reaction of
2-chlorothioa-zole (18) with n-butyllithium at low temperature
followed by addition of 2-chloro-6-methylphenyl isocyanate
(19) gave anilide 20 in 86% yield. The amide 20 was
protected as corresponding 4-methoxy benzyl (PMB) anilide
22 in 95% yield which was subsequently reacted with 4-
amino-6-chloro-2-methylpyrimidine (23) in the presence of
sodium hydride in hot THF to give compound 24 in 83%
yield. The PMB protecting group was then removed with
triflic acid to give compound 25 in 99% yield. Compound 25
was reacted with 1-(2-hydroxyethyl)piperazine (26) in refluxing
dioxane to give dasatinib (III) in 91% yield.
Drug interactions
Potentially hazardous interactions with other drugsAntacids: absorption possibly reduced by antacids,
give at least 2 hours apart.Antibacterials: metabolism accelerated by rifampicin
- avoid.Antipsychotics: avoid with clozapine, increased risk
of agranulocytosis.Antivirals: avoid with boceprevir.Ulcer healing drugs: avoid with histamine H2
antagonists; concentration reduced by proton pump
inhibitors.
Metabolism
Dasatinib is extensively metabolised, mainly via the
cytochrome P450 isoenzyme CYP3A4, forming an active
metabolite.Elimination is predominantly in the faeces, mostly as
metabolites. Following a single oral dose of [14C]-labelled
dasatinib, approximately 89% of the dose was eliminated
within 10 days, with 4% and 85% of the radioactivity
recovered in the urine and faeces, respectively. Unchanged
dasatinib accounted for 0.1% and 19% of the dose in
urine and faeces, respectively, with the remainder of the
dose as metabolites.
References
1) Lombardo et al. (2004), Discovery of N-2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a duel Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays; J. Med. Chem., 47 6658
2) Nam et al. (2005), Action of the Src family kinase inhibitor dasatinib (BMS-354825), on human prostate cancer cells; Cancer Res., 65 9185
3) Johnson et al. (2005), Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells; Clin. Cancer Res., 11 6924
Check Digit Verification of cas no
The CAS Registry Mumber 302962-49-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,2,9,6 and 2 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 302962-49:
(8*3)+(7*0)+(6*2)+(5*9)+(4*6)+(3*2)+(2*4)+(1*9)=128
128 % 10 = 8
So 302962-49-8 is a valid CAS Registry Number.
InChI:InChI=1/C22H26ClN7O2S.H2O/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31;/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27);1H2
302962-49-8Relevant articles and documents
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
Lombardo, Louis J.,Lee, Francis Y.,Chen, Ping,Norris, Derek,Barrish, Joel C.,Behnia, Kamelia,Castaneda, Stephen,Cornelius, Lyndon A. M.,Das, Jagabandhu,Doweyko, Arthur M.,Fairchild, Craig,Hunt, John T.,Inigo, Ivan,Johnston, Kathy,Kamath, Amrita,Kan, David,Klei, Herbert,Marathe, Punit,Pang, Suhong,Peterson, Russell,Pitt, Sidney,Schieven, Gary L.,Schmidt, Robert J.,Tokarski, John,Wen, Mei-Li,Wityak, John,Borzilleri, Robert M.
, p. 6658 - 6661 (2004)
A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole- 5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.
Scalable and impurity-free process for dasatinib: Src and BCR-Abl inhibitor
Buchappa,Sagar Vijay Kumar,Durga Prasad,Aparna
, p. 1621 - 1628 (2018)
An efficient, telescopic, impurity-free and scalable process for Bcr-Abl and Src family tyrosine kinase inhibitor for synthesis of Dasatinib with high yield and purity is described.
Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors
Liu, Lu,Hussain, Muzammal,Luo, Jinfeng,Duan, Anna,Chen, Chaonan,Tu, Zhengchao,Zhang, Jiancun
, p. 420 - 427 (2017)
Novel dasatinib analogues as DDR1 and DDR2 inhibitors were designed and synthesized. The synthesized compounds were screened for DDR1 and DDR2 kinase inhibitory and cancer cell proliferation inhibitory activities. Some of the compounds showed the potent i
HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF
-
, (2021/11/04)
The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.
HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF
-
, (2020/05/30)
The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.
N-phenyl-2-(pyrimidin-4-ylamino)thiazol-5-carboxamide derivatives, pharmaceutically acceptable salts thereof and a whitening material composition containing the same as an active ingredient
-
, (2020/11/03)
The present invention relates to a whitening material composition comprising an N-phenyl-2-(pyrimidin-4-ylamino)thiazole-5-carboxamide derivative as an active ingredient. Since the whitening material composition provided in one aspect of the present invention has an excellent effect of inhibiting the promotion of cell melanogenesis even when a small amount thereof is used, a cosmetic product for skin whitening and a product for preventing, alleviating, and treating melanin hyperpigmentation diseases can be usefully used.
Preparation method of dasatinib hydrate
-
Paragraph 0027; 0033-0035, (2020/06/20)
The invention provides a preparation method ofdasatinib hydrate. The dasatinib hydrate is prepared by reacting a compound shown asstructural formula I in a compound a and a compound b. According to the technical scheme provided by the invention, the high-quality dasatinib hydrate can be obtained, tedious separation and purification steps are avoided, the operation is simple, the waste of raw materials is also avoided, the production cost is reduced, and the method is more suitable for industrial production.
Preparation method for dasatinib monohydrate
-
Paragraph 0040; 0049-0050, (2020/07/13)
The invention provides a preparation method for a dasatinib monohydrate. The dasatinib monohydrate is obtained by a reaction of dasatinib in an ethanol aqueous solution. According to a technical scheme of the invention, the high-quality dasatinib monohydrate can be obtained; tedious separation and purification steps are avoided; operation is simple; the waste of raw materials is also avoided; theproduction cost is reduced; and the preparation method is more applicable to industrial production.
POLYMORPHIC FORMS OF DASATINIB
-
Page/Page column 69; 70; 77; 78; 79; 80; 81, (2019/01/22)
The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±) – 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib- butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib
Preparation method of Dasatinib
-
, (2019/02/10)
The invention provides a preparation method of Dasatinib. 2-Bromothiazole-5-formic acid and 2-methyl-4-amino-6-cloro pyridine are adopted as raw materials, a first-time substitution reaction is performed, the raw materials and 4-(2-acetyl oxyl) Ethylpiperazine are subjected to a second-time substitution reaction to prepare 2-[[6-[4-(2-acetyloxy ethyl)-1-piperazinyl]-2-methl-4-pyrimidyl]amino]-5-Febuxostat; then, the product and an acylating chlorination reagent are subjected to an acylating chlorination reaction and subjected to an amidation reaction with 2-cholo-6-methylaniline, and finally ahydrolysis reaction is performed to remove acetyl to prepare dasatinib. The raw materials are cheap and easy to obtain and low in cost; the technological process is simple, operation is safe and easy, technological wastewater generation amount is small, and the method is environmentally friendly; raw materials and intermediate products stability is suitable, the reaction activity and selectivityare high, reaction conditions are easy to obtain, side reactions are few, the manufactured dasatinib contains few impurities, the purity and yield are high, and industrial production of dasatinib is facilitated.
